By: IPP Bureau
Last updated : May 18, 2026 5:43 am
US formulations grew 11% to Rs. 564 crore as Alembic enters US branded pharmaceuticals market with launch of Pivya
Alembic Pharmaceuticals Limited reported a resilient performance for the fourth quarter ended March 31, 2026, with consolidated revenue from operations rising 4% year-on-year to Rs. 1,848 crore, supported by strong traction in its US formulations business and steady growth in domestic branded formulations.
The company’s Profit After Tax (PAT) surged 29% YoY to Rs. 203 crore, while EBITDA before R&D expenses grew 8% YoY to Rs. 455 crore. Pre-R&D EBITDA margin for the quarter stood at a healthy 25%, reflecting operational discipline amid ongoing investments in growth businesses.
The quarter also marked a strategic milestone for the Vadodara-headquartered drug maker as it entered the US branded pharmaceuticals space through the launch of Pivya under Alembic Therapeutics, its step-down wholly owned subsidiary.
Commenting on the results, Pranav Amin said, “Q4FY26 reflects disciplined execution across our businesses, supported by continued focus on profitability, operational delivery and long-term growth investments. We delivered revenue growth across key segments while maintaining healthy pre-R&D operating margins. During the quarter, we marked our entry into the Branded Business in the US, beginning with the launch of Pivya, opening a new avenue for long-term value creation.”
Alembic’s US formulations business continued to be the key growth driver during the quarter, registering an 11% rise in revenue to Rs. 564 crore. The company launched six products in the US market during the quarter and secured four ANDA approvals, strengthening its pipeline and market presence in the highly competitive generics segment.
The newly launched Pivya is positioned as a first-line oral antibiotic for uncomplicated urinary tract infections (uUTIs) in women. The company believes the therapy area presents a significant opportunity due to limited innovation and new product introductions over the last decade.
On the domestic front, Alembic’s India Branded Business reported revenue of Rs. 568 crore, up 4% year-on-year. The company witnessed encouraging traction in key therapy areas including gynaecology, gastrology, ophthalmology and animal healthcare, while also adding two new products to its portfolio during the quarter.
The Ex-US generics business posted revenue of Rs. 369 crore, while the API business grew modestly by 2% to Rs. 347 crore.
For the full year FY26, Alembic reported consolidated revenue from operations of Rs. 7,345 crore, reflecting a 10% increase over the previous fiscal, underlining broad-based growth across its formulations and API businesses.